

0756-0118P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/720738

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.

PCT/EP99/04418

INTERNATIONAL FILING DATE

June 25, 1999

PRIORITY DATE CLAIMED

June 26, 1998

## TITLE OF INVENTION

FUNCTIONAL VITAMIN D DERIVATIVES AND A METHOD FOR DETERMINING 25-HYDROXY-VITAMIN D\*\*

## APPLICANT(S) FOR DO/EO/US

ARMBRUSTER, Franz, Paul; VOELTER, Wolfgang; SCHWING, Jens; BIRKMAYER, Christian

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau. WO 99/62711
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(3)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. and International Search Report with cited documents
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:  
PCT/ISA/210  
Fifteen (15) sheets of formal drawings

\*\*AND 1 $\alpha$ ,25-DIHYDROXY-VITAMIN D

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
69/720338		PCT/EP99/04418		0756-0118P	

<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p><b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):</b>          Neither international preliminary examination fee (37 CFR 1.482)          nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO          and International Search Report not prepared by the EPO or JPO. .... <b>\$1,000.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) not paid to          USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO          but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. .... <b>\$710.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO          but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO          and all claims satisfied provisions of PCT Article 33(1)-(4). .... <b>\$100.00</b></p> <p><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></p> <p>Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30          months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;"></th> <th style="width: 20%;"></th> </tr> <tr> <td>Total Claims</td> <td>14 - 20 =</td> <td>0</td> <td>X \$18.00</td> <td>\$</td> <td>0</td> </tr> <tr> <td>Independent Claims</td> <td>2 - 3 =</td> <td>0</td> <td>X \$80.00</td> <td>\$</td> <td>0</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes</td> <td>+ \$270.00</td> <td>\$</td> <td>270.00</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td>\$</td> <td>1260.00</td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable.          Applicant claims Small Entity Status in accordance with 37 CFR 1.27.</td> <td>\$</td> <td>-630.00</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>SUBTOTAL =</b></td> <td>\$</td> <td>630.00</td> </tr> <tr> <td colspan="4">Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30          months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>\$</td> <td>0</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL NATIONAL FEE =</b></td> <td>\$</td> <td>630.00</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be          accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +</td> <td>\$</td> <td>0</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL FEES ENCLOSED =</b></td> <td>\$</td> <td>630.00</td> </tr> <tr> <td colspan="4"></td> <td style="text-align: right;">Amount to be:</td> <td>\$</td> </tr> <tr> <td colspan="4"></td> <td style="text-align: right;">refunded</td> <td></td> </tr> <tr> <td colspan="4"></td> <td style="text-align: right;">charged</td> <td>\$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			Total Claims	14 - 20 =	0	X \$18.00	\$	0	Independent Claims	2 - 3 =	0	X \$80.00	\$	0	MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes			+ \$270.00	\$	270.00	<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	1260.00	Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status in accordance with 37 CFR 1.27.				\$	-630.00	<b>SUBTOTAL =</b>				\$	630.00	Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0	<b>TOTAL NATIONAL FEE =</b>				\$	630.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	0	<b>TOTAL FEES ENCLOSED =</b>				\$	630.00					Amount to be:	\$					refunded						charged	\$	<p><b>CALCULATIONS</b></p> <p><b>PTO USE ONLY</b></p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																																																		
Total Claims	14 - 20 =	0	X \$18.00	\$	0																																																																																
Independent Claims	2 - 3 =	0	X \$80.00	\$	0																																																																																
MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes			+ \$270.00	\$	270.00																																																																																
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	1260.00																																																																																
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims Small Entity Status in accordance with 37 CFR 1.27.				\$	-630.00																																																																																
<b>SUBTOTAL =</b>				\$	630.00																																																																																
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0																																																																																
<b>TOTAL NATIONAL FEE =</b>				\$	630.00																																																																																
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	0																																																																																
<b>TOTAL FEES ENCLOSED =</b>				\$	630.00																																																																																
				Amount to be:	\$																																																																																
				refunded																																																																																	
				charged	\$																																																																																


a. ☒ A check in the amount of \$ **630.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account. No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
 overpayment to Deposit Account No. 02-2448.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

Send all correspondence to:  
**Birch, Stewart, Kolasch & Birch, LLP** or Customer No. 2292  
**P.O. Box 747**  
**Falls Church, VA 22040-0747**  
**(703)205-8000**

  
 SIGNATURE  
**MURPHY, GERALD M., JR.**  
 NAME

**#28,977 (GMM)**  
 REGISTRATION NO.

/rem December 22, 2000

PATENT  
0756-0118P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: ARMBRUSTER, Franz P et al.  
Int'l. Appl. No.: PCT/EP99/04418  
Appl. No.: NEW Group:  
Filed: December 22, 2000 Examiner:  
For: FUNCTIONAL VITAMIN D DERIVATIVES  
AND A METHOD FOR DETERMINING 25-  
HYDROXY-VITAMIN D AND 1 $\alpha$ ,25-  
DIHYDROXY-VITAMIN D

PRELIMINARY AMENDMENT

**BOX PATENT APPLICATION**

Assistant Commissioner for Patents  
Washington, DC 20231

December 22, 2000

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:


Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/EP99/04418 which has an International filing date of June 25, 1999, which designated the United States of America.--

**IN THE CLAIMS:**

Please cancel claims 1-13 and substitute therefore the following new claims.

5



10

R represents a 25-hydroxy side-group of vitamin D<sub>2</sub>  
or of vitamin D<sub>3</sub>;

Y represents hydrogen or hydroxy;

15

characterised by the steps;

20

b) addition of lithium hydride and transfer of the 25-hydroxy group into the lithium alcoholate and subsequent reduction of the nitrile group with lithium aluminium hydride; and

25

15. Method according to claim 14, wherein the functional group A is selected from biotin, digoxigenin, tyrosine, FITC substituted tyrosine, substituted amino acids, characteristic amino acids and peptide sequences, FITC, proteins and peptide groups, protein-A, protein-G and vitamin D derivatives.
16. Method according to claim 14, wherein the functional group A is 25-hydroxy vitamin D or 1 $\alpha$ ,25-dihydroxy vitamin D.
17. Method according to claim 14, wherein the functional vitamin D group is coupled in the 3 $\beta$ -position via an ether bridge with the spacer group.
18. Method according to claim 14, wherein step c) is effected with biotinyl-N- $\epsilon$ -amino caproyl-hydroxy-succinimide ester (LC-BHNS) or an activated biotinylation reagent.
19. Method according to claim 14, wherein the spacer group is an amino carboxylic acid radical, an amino undecanoic acid radical or an amino polyether radical.
20. Method of producing the 3-amino propyl-25-hydroxy- or 3-amino propyl-1 $\alpha$ ,25-dihydroxy vitamin D intermediate compound, characterised by the method steps a) and b) according to claim 14.
21. Method for the quantitative detection of 25-hydroxy- and 1 $\alpha$ ,25-dihydroxy vitamin D metabolite in a sample, characterised in that a vitamin D derivative is obtained with a method according to claim 14, and is


employed as a binding partner.

22. Method according to claim 21, wherein the method is a competitive immunoassay, selected from RIA, EIA/ELISA, LiA and FiA.

23. Method according to claim 21, wherein the method is a sandwich immunoassay, selected from IRMA, IEMA/EUA, ILMA (immunoluminescence assay) and IFMA (immunofluorescence assay).

24. Reagent kit for the detection of 25-hydroxy- and 1 $\alpha$ ,25-dihydroxy vitamin D metabolites, characterised in that it contains a standardised quantity of solid or solution of a vitamin D-derivative which is manufactured in accordance with claims 14.

25. Vitamin D-derivative of the formula:



wherein:

R represents a 25-OH side group of vitamin D<sub>2</sub> or D<sub>3</sub>;

Y represents hydrogen or hydroxy; and

X represents a substituted or non-substituted

hydrocarbon group of 0.8 to 4.2 nm length, which may have usual heteroatoms such as S, O, N or P.

- 5 26. Vitamin D derivative according to claim 25, obtained by method according to claim 14, wherein in step c) two vitamin D aminopropyl compounds are coupled by means of condensation with a dicarboxylic acid.--

#### REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete multiple dependents and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr., #28,977

GMM/rem  
0756-0118P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

(Rev. 04/19/2000)

15/PRTS

09/720338  
528 Rec'd PCT/PTO 22 DEC 2000

PCT/EP99/04418

HL-00873.002/UMB 15.12.2000

FUNCTIONAL VITAMIN D DERIVATIVES AND METHOD OF DETERMINING  
25-HYDROXY- AND 1 $\alpha$ ,25-DIHYDROXY VITAMIN D

- 5 The invention relates to derivatives of 25-hydroxy vitamin D, a synthesis thereof, and a method of measuring 25-hydroxy vitamin D and 1,25-dihydroxy vitamin D in samples.
- 10 The D-vitamins or calciferols arise from their provitamins through a cleavage, catalysed by sunlight, of the B-ring in the sterane rings. Their most important representatives are vitamin D<sub>3</sub> (cholecalciferol) and vitamin D<sub>2</sub> (ergocalciferol), which differ slightly only in the side chains, but
- 15 which - so far as known - are similarly metabolised and have identical biological effects. Whereas provitamin D<sub>2</sub> must be taken in with the food, the provitamin D<sub>3</sub> can be formed in the human organism. So far as not more specifically designated by means of indices, the term
- 20 vitamin D comprehends in the following in general all vitamin D forms. Vitamin D formed in the skin or taken in with food is bound in the plasma by vitamin D binding or transport proteins (DBP), transported to the liver and there metabolised to 25-hydroxy vitamin D (25-OH-D). The
- 25 vitamin D binding protein DBP is also known as Gc-globulin or *group specific component* (J.G. Haddad in J. Steriod Biochem. Molec. Biol. (1995) 53, 579-582). Over 95% of the 25-hydroxy vitamin D measurable in the serum is as a rule 25-hydroxy vitamin D<sub>3</sub>. 25-Hydroxy vitamin D<sub>2</sub> is only found
- 30 in greater proportions if the person is receiving medication with vitamin D<sub>2</sub> or, as is frequently the practice in the United States, foodstuffs are supplemented with vitamin D<sub>2</sub>.




25-Hydroxy vitamin D is the prevailing vitamin D metabolite in the blood circulation and its concentration in the serum generally indicates the vitamin D status, i.e. the extent to which vitamin D is available to the organism. If needed, 25-hydroxy vitamin D is metabolised in the kidneys to  $1\alpha,25$ -dihydroxy vitamin D, a hormone-like substance with great biological activity. The determination of  $1\alpha,25$ -dihydroxy vitamin D indicates how much vitamin D is present in the activated form.

10

The determination of 25-hydroxy vitamin D in a sample is preferably effected in accordance with the principle of competitive protein binding analysis, whereby on the basis of the displacement of radioactive 25-hydroxy vitamin D from the binding sites of a vitamin D binding protein, the 25-hydroxy vitamin D present in the sample can be quantified. Also, over the last several years, radioimmunoassays using  $^{125}\text{I}$ -labelled vitamin D derivatives and antibodies for vitamin D derivatives have established themselves in diagnosis. The data of the normal level of 25-hydroxy vitamin D in serum vary depending on the laboratory. It is, however, agreed that the concentration of 25-hydroxy vitamin D in the serum is as a rule greater than 5 ng/ml and smaller than 80 ng/ml. The competitive protein binding analysis requires the use of a radioactive vitamin D derivative which must have the same protein binding characteristics as 25-hydroxy vitamin D. The same applies also for the competitive binding analysis for the biologically active  $1\alpha,25$ -dihydroxy vitamin D and other vitamin D metabolites.

European patent specifications 0 312 360 and 0 363 211, and Tanabe et al. in J. Chem. Soc., Chem. Commun. 1989, 1220-1221 and J. Nutri. Sci. Vitaminol., 1991, 37, 139-147, disclose various  $^{125}\text{I}$ -labelled hydroxy- and dihydroxy

vitamin D derivatives and their use in binding studies. These derivatives suffer the disadvantages that they are problematic to produce and are extremely labile. Light, radioactive rays, protons, hydrogen, enzymes, free radicals or the presence of iodine in free or bound form have great effect on the configuration and the binding characteristics of the vitamin D derivatives to vitamin D binding protein DBP or specific antibodies. Above all, they can cause or catalyse a rotation of the A-ring in the sterane system. The  $3\beta$ -hydroxy-group of the vitamin D molecule is thereby rotated into the pseudo- $1\alpha$ -position, so that 5,6-trans-vitamin D is obtained. The so-called pseudo- $1\alpha$ -hydroxy-analogs of vitamin D may be metabolised similarly to vitamin D, but they have a structure which is different in significant points and are not bound or are significantly more poorly bound by vitamin D binding proteins such as for example DBP/Gc-Globulin or anti-vitamin D antibodies.



The above-described re-arrangement is to be understood as an example. Other chemical reactions and re-arrangements also occur. The same applies for  $^3H$ - or  $^{14}C$ -labelled vitamin D derivatives. These vitamin D derivatives are likewise not so stable that they permit a reliable binding analysis. The radioactive marking additionally increases

the costs of storage, transport and disposal and is generally disadvantageous for health and the environment. Further the half-life of <sup>125</sup>iodine is relatively short. On the other hand, a competitive binding analysis with <sup>3</sup>H- and <sup>14</sup>C-labelled vitamin D derivatives requires particular scintillation counters and is more demanding in terms of equipment, with largely the same problems.


Ray et al., in Biochemistry, 1991, 30, 4809-4813 disclose the coupling of vitamin D<sub>3</sub> with various colouring groups. The detection sensitivity for dye-labelled vitamin D<sub>3</sub> derivatives is, however, too small that one might use them in a competitive binding analysis for natural vitamin D metabolites, apart from the fact that the dye-labelled derivatives are not stable in serum and further are particularly light-sensitive.

It is the object of the invention to make available vitamin D derivatives which can be employed in a competitive binding analysis or quite generally in immunoassays of vitamin D metabolites such as 25-hydroxy vitamin D and 1,25-dihydroxy vitamin D. This presumes the following properties: first, that for the vitamin D derivatives, a detection sensitivity exists which is higher than, or lies in a lower range of concentrations than, the concentration of the sought after vitamin D metabolites in the samples; second, that the derivatives are stable in serum, plasma or urine under the usual protonic conditions and are stable with the respect to serum enzymes; and finally, third, that the derivatives are sufficiently stable with regard to light and storage, over weeks and months. This object is achieved by means of vitamin D derivatives having the formula

5

10

15



(I)

wherein:

- O represents the oxygen atom of an ether group;
- 20 X represents a substituted or non-substituted hydrocarbon group of 0.8 to 4.2 nm length, preferably a C8- to C12-group, which may have the usual heteroatoms such as S, O, N or P, most particularly preferred an hexamido-, octamido- or decamido-amidopropylether linker group;
- 25 Y represents hydrogen or a hydroxy group;
- A a functional group which is bound with high affinity by a binding protein such as an antibody or vitamin D binding protein DBP;
- 30 R the side group of a vitamin D metabolite, preferably the side group of vitamin D<sub>2</sub> or D<sub>3</sub>, particularly preferably the 25-hydroxylated side group of vitamin D<sub>2</sub> or D<sub>3</sub>.

35 A high affinity is present when the dissociation constant

SCANNED, # \_\_\_\_\_


(K) between the binding protein, e.g. the antibody or DBP, and the antigen or the functional group A is greater than  $10^8$ . A dissociation constant greater than  $10^{16}$  is advantageous for many applications. In a preferred embodiment A is selected from biotin, digoxigenin, tyrosine, substituted tyrosine, substituted amino acids, characteristic amino acid and peptide sequences, FITC, proteins and protein groups such as protein A and protein G or a further vitamin D derivative, most particularly preferred 25-hydroxy vitamin D.

The spacer group X is preferably selected from substituted and non-substituted C-bodies having a length of 0.8 to 4.2 nm, preferably about 0.12 nm. Particularly preferred is an amino carboxylic acid, in particular an amino undecanoic acid, peptide and keto group or a substituted or non-substituted amino polyether radical having a length of 0.8 to 4.2 nm, preferably about 0.9 to 1.5 nm. This spacing between the group A and the binding or detection site for the vitamin D radical is necessary so that the binding proteins can bind to the binding site concerned in each case and thereby do not interfere with one another. It is to be taken into consideration that for example for the vitamin D binding protein DBP (Gc-globulin) the 19-methylene group, if applicable the 1-hydroxy group of the A-ring and the vitamin D side chain belong to the recognition site and are received in a binding pocket. Similar applies also for specific antibodies against the various vitamin D derivatives. If the spacer group X is too short no further binding protein can bind to the selected functional group A along with the vitamin D binding protein. For the preferred example, this means that when the functional biotin group is located within the binding pocket of the vitamin D binding protein it is no longer accessible for the second binding protein, for example the streptavidin. On the other hand, if the spacer

group X is too long, molecular folding can arise which likewise hinders the simultaneous binding of two binding partners.

5 Further, the spacer group in accordance with the invention surprisingly has a steric effect, since it clearly actively hinders a 180° degree rotation of the A-ring. It is suspected, without being restricted to this theory, that the 3β-oxygen atom of the ether group on the A-ring  
10 is hydrated corresponding to a natural hydroxy group and so prevents an attack on the 5,6-double bond, apart from other electronic and steric effects. A further important aspect is that the ether group in accordance with the invention cannot be dissociated by the esterases which are  
15 always present in serum or plasma.

Most particularly preferred is 25-hydroxy vitamin-D<sub>3</sub>-3β-3' [6-N-(biotinyl)hexamido]amidopropylether of the formula  
II



and the 1α-hydroxy- and vitamin D<sub>2</sub> analogs.

Further preferred are derivatives which contain as the  
35 second functional group a vitamin D radical. The advantage



steps: a) cyanoethylation of the 3-hydroxy group of vitamin D or 25-hydroxy vitamin D with acrylonitrile in a suitable solvent such as acetonitrile in the presence of potassium hydride and tertiary butanol; b) reduction of the resulting nitrile group with a mixture of lithium hydride and lithium aluminium hydride to an amine; and c) linking a spacer group, if appropriate with a functional group A, to the amine, for example biotinylation of the compound with an active biotinylation reagent such as LC-BHNS or, to obtain a vitamin D derivative in accordance with formula III, coupling of two amino-vitamin D groups, by means of condensation, with a dicarboxylic acid such as sebacinic acid, by means of carbodiimide.

The method in accordance with the invention for the production of functional vitamin D derivatives gives higher yields with shorter reaction times. Different from conventional methods, there is effected namely in step a) the cyanoethylation of the 3-hydroxy group in the presence of potassium hydride and tertiary butanol. By this means it is achieved that cyanoethylation is effected only at the 3-hydroxy group of vitamin D and the other hydroxy groups of the vitamin D are protected from reaction. The reaction is effected at 0 to 20°C, preferably at 5 to 8°C in a neutral solvent medium such as acetonitrile.

In the subsequent reduction, the nitrile group of the cyanoethylether is quantitatively reduced into the amine, which can then be relatively simply linked with another functional group, for example by means of reaction with a commercial available biotinylation reagent.

The invention includes additionally the use of the functional vitamin D derivatives in accordance with the invention in methods for detecting 25-hydroxy- and 1 $\alpha$ ,25-



10220" 3462460

dihydroxy vitamin D in serum, plasma, urine or another sample. Here, the functional vitamin D conjugate in accordance with the invention is employed either as an intermediate, whereby the vitamin D binding protein and native vitamin D metabolites compete for the binding site, or is employed itself as competitive binding component to native vitamin D. The quantitative detection method is preferably an EIA, ELISA, RIA, IRMA, LiA or ILMA, FIA or IFMA in test systems which are to be worked manually or in versions adapted to automatic testing machines, in liquid phase as well as solid phase technology.

A particularly preferred method for detecting 25-hydroxy- and 1 $\alpha$ ,25-dihydroxy vitamin D derivatives include the steps: a) coating a carrier with streptavidin, b) addition of one or a plurality of a multifunctional biotin-vitamin D derivatives, c) addition of the sample and a defined quantity of vitamin D binding protein, d) detection of the bound binding protein with labelled anti-vitamin D binding protein antibodies. The labelling of the anti-vitamin D binding protein antibodies can be direct, for example a radioactive marking, or also indirect, for example by an enzyme or an active enzyme fragment such as peroxidase, which is capable of catalysing a colour reaction.

A further preferred method for detecting 25-hydroxy- and 1 $\alpha$ ,25-dihydroxy vitamin D derivatives includes the steps: a) coating a carrier with anti-vitamin D binding protein antibodies, b) adding the vitamin D binding protein, c) adding the sample and a defined quantity of biotin-vitamin D derivative, d) detecting the quantity of bound derivative with labelled streptavidin. The streptavidin is preferably indirectly labelled with peroxidase; the carrier is preferably a reaction vial wall, for example of a microtitration plate, or particles of polymer or

magnetic material or both, for example plastic or cellulose microparticles.

These methods make possible a non-radioactive quantitative  
5 detection of 25-hydroxy- and 1,25-dihydroxy vitamin D,  
without extensive safety measures being required. The  
competitive methods proposed here are thus suitable for  
routine investigations within in the scope of osteoporosis  
prophylaxis, in the case of a suspected D-hypovitaminosis  
10 or D-hypervitaminosis, for diagnostics in general, and in  
research.

A further aspect of the invention is a kit for detecting  
vitamin D metabolites such as 25-hydroxy- and 1,25-  
15 dihydroxy vitamin D, which inter alia contains the  
functional vitamin D derivative in accordance with the  
invention. The kit includes a vitamin D binding protein  
(Gc-globulin) which can be freely selected, anti-vitamin D  
binding protein antibodies, streptavidin and pre-prepared  
20 or non-pre-prepared microtitration plates and/or magnetic  
or other microparticles and other reagents.

Further advantages, features and embodiments of the  
invention are indicated in the following examples and the  
25 accompanying drawings, which show:

Fig. 1 the schematic path of synthesis for the bifunc-  
tional vitamin D derivative 25-hydroxy vitamin-  
D<sub>3</sub>-3 $\beta$ -3' [6-N- (biotinyl) hexamido] amidopropylether)  
30 in accordance with the invention;

Fig. 2, 3  
and 4 schematic representations of various ELISAs for  
the detection of 25-OH-vitamin D with the aid of  
35 the 25-OH-vitamin D conjugate in accordance with

the invention;

Fig.5A the calibration curve of a competitive ELISA for  
25-OH-vitamin D according to Figure 2;

5

Fig.5B calibration curves for ELISAs in accordance with  
Figure 5A, having 3, 60 and 100 days old 25-OH-  
vitamin D biotin tracer;

10 Fig.5C the calibration curve of a competitive ELISAs  
for 1,25-dihydroxy vitamin D, analogous to  
Figure 2;

Fig. 6

15 and 7 schematic representations of competitive RIAs  
for 25-OH-vitamin D with the aid of the 25-OH-  
vitamin D conjugate in accordance with the  
invention;

20 Fig. 8, 9

and 10 schematic representations of competitive,  
radioactive IRMAs for 25-OH-vitamin D with the  
aid of the 25-OH-vitamin D conjugate in  
accordance with the invention;

25

Fig. 11

and 12 schematic representations of competitive ELISAs  
with the employment of microparticles;

30 Fig. 13 schematic representations of a competitive  
binding assay for 25-OH-vitamin D with the aid  
of a 25-OH-vitamin D conjugate in accordance  
with the invention and a directly labelled  
vitamin D binding protein;

35

Fig. 14 a block diagram of the comparison of the 1,25-

dihydroxy vitamin D-content in serum from dialysis patients and normal patients.

Fig. 1 shows the route of synthesis in accordance with the invention for the production of a bifunctional 25-OH vitamin D conjugate. First, 25-OH vitamin D is cyanoethylated in a mixture of acetonitrile, potassium hydride, and tertiary butanol with acrylonitrile. Due to the presence of the potassium hydride, acting as a base, and due to the presence of tertiary butanol for avoiding non-specific reactions at the 25-hydroxy group, it is achieved that the 3-hydroxy group of the vitamin D is selectively cyanoethylated. The yield of 25-OH vitamin D-3 $\beta$ -cyanoethylether amounts, as a rule, to about 74% with a reaction time of 40 minutes.

After conventional preparation, the 25-OH vitamin D-3 $\beta$ -cyanoethylether is mixed with lithium hydride and the 25-hydroxy group transferred into the lithium alcoholate. There follows a reduction of the nitrile with LiAlH<sub>4</sub> to 25-OH-vitamin-D-3 $\beta$ -3'-amino propylether. This step is quantitative, without by-products arising. Finally there is effected if necessary a biotinylation with an active biotinylation reagent such as LC-BHNS (biotinyl-N- $\epsilon$ -amino caproyl-hydroxy-succinimide ester). The resulting spacer group X has, corresponding to the amino caproyl chain, a length of about 0.8 to 0.9 nm.

25-OH-vitamin-D-3 $\beta$ -3' [6-N-(biotinyl)hexamido]amidopropyl-ether is temperature stable and can be stored over many months in an aqueous, slightly acid matrix. Since the compound can not be cleaved by serum enzymes, it is ideally suited for routine diagnostic tests in serum, plasma and urine.

Fig. 2 shows a schematic representation of a competitive ELISA for 25-OH-vitamin D. Here, the 25-OH-vitamin D conjugate (25-OH-vitamin-D-3 $\beta$ -3' [6-N-(biotinyl)hexamido]-amidopropylether) is bound via streptavidin to a solid phase. Then, in liquid phase, there is effected the competitive binding of vitamin D binding protein and 25-OH-vitamin D from a standard or a sample to the 25-OH-vitamin D conjugate. The detection is effected by means of peroxidase labelled antibodies against the vitamin D binding protein. The skilled person knows that also other marker enzymes can be employed, for example alkaline phosphatase or galactosidase, etc.

Fig. 3 shows a schematic representation of a competitive, non-radioactive ELISA whereby the vitamin D binding protein is first bound to the solid phase via anti-vitamin D binding protein antibodies. There is then effected, in liquid phase, a competitive binding of 25-OH-vitamin D biotin and 25-OH-vitamin D from a standard or a sample. For detection, peroxidase-labelled streptavidin is then employed. The indicated principle can of course be transferred to other tracer groups instead of biotin and to other marker enzymes, as indicated above.

Fig. 4 shows a schematic representation of a competitive ELISA, whereby the vitamin D binding protein is directly bound to the solid phase. The competitive binding of 25-OH-vitamin D<sub>3</sub>-biotin and 25-OH-vitamin D<sub>3</sub> from a standard or a sample is effected in liquid phase and peroxidase-labelled streptavidin is employed for quantitative detection.

Fig. 5A-C show the typical calibration curves of competitive ELISAs with 25-OH- or 1,25-dihydroxy vitamin-D<sub>3</sub>-biotin, in accordance with the principle shown in Fig.

2. The quantity of bound vitamin D binding protein was determined by means of a standardised colour reaction with peroxidase-coupled anti-vitamin D binding protein antibodies and tetramethylbenzidine (TMB) as substrate.

5 Alternative substrates would be, for example, OPD (1,2-phenyldiamine x 2 HCl), ABTS and others. For the calibration curve, vitamin D samples with concentrations of 0, 8, 20, 50, 125 and 312 nMol/l were employed. The ordinate shows the optical density as the mean value of

10 two measurements at 450 nm; the abscissa shows the concentration of 25-OH- or 1,25-dihydroxy vitamin D in nMol/l.

Fig. 6 shows the schematic representation of a competitive protein binding test (CPBA), wherein 25-OH-vitamin-D<sub>3</sub>-biotin and 25-OH-vitamin D, from a standard or sample, compete in liquid phase for the binding site of the vitamin D binding protein. <sup>125</sup>I-labelled streptavidin is employed for the quantitative detection.

Fig. 7 shows the schematic representation of a competitive radioimmunoassay (RIA), wherein 25-OH-vitamin-D-biotin and 25-OH-vitamin D from a standard or a sample compete in liquid phase for the binding site of an anti-vitamin D-antibody. <sup>125</sup>I-labelled streptavidin is employed for quantitative detection. If the detection is effected by means of a streptavidin which is not radioactive but is labelled with a fluorophore or luminophore, so-called LIA or FIA assays are involved.

Fig. 8 shows schematic representation of a 25-OH-vitamin D-IRMA. First, 25-OH-vitamin-D-biotin is bound to the solid phase via streptavidin. The competitive binding of vitamin D-binding protein to the conjugate and 25-OH-vitamin-D<sub>3</sub> from a standard or a sample is then effected in liquid phase. The quantity of the conjugate-bound binding

protein is determined with  $^{125}\text{I}$ -labelled antibodies.

Fig. 9 is the schematic representation of an IRMA sandwich technique (immunoradiometric assay). For this purpose, anti-vitamin  $\text{D}_3$  antibodies are coupled to the solid phase. Vitamin D binding proteins then bound to these. The competition takes place in the next step between the 25-OH-vitamin D conjugate and 25-OH-vitamin D from a standard or a sample. The determination of the quantity of the bound conjugate is effected by means of a  $^{125}\text{I}$ -labelled streptavidin.

Fig. 10 shows the schematic representation of a further IRMA sandwich technique. First, vitamin  $\text{D}_3$  binding proteins are coupled to the solid phase. There is then effected thereupon the competitive binding between the 25-OH-vitamin  $\text{D}_3$  conjugate and 25-OH-vitamin  $\text{D}_3$  from a standard or a sample. The quantity of bound conjugate is determined by means of  $^{125}\text{I}$ -labelled streptavidin.

Fig. 11 shows the schematic representation of a competitive ELISA employing microparticles. Here, 25-OH-vitamin D-biotin is bound to microparticles via streptavidin. 25-OH-vitamin D derivative is then bound thereto. Vitamin D binding protein and the sample concerned are then added in liquid phase. Binding proteins and 25-OH-vitamin  $\text{D}_3$  from a standard or a sample compete for the binding site of the conjugate. The bound components are separated in that they are held back via the microparticles by a magnet, whereas the remainder with the non-bound substances is removed. The quantity of coupled binding protein is determined in a 2-stage process with a primary antibody against vitamin D binding protein and a secondary peroxidase-labelled antibody.

Fig. 12 shows a schematic representation of a competitive

ELISA employing microparticles. 25-OH-vitamin-D-biotin is bound to microparticles via streptavidin. Then the liquid sample with 25-OH-vitamin D<sub>3</sub> (from a standard or a sample) is added, as is a non-saturating quantity of antibodies. 5 The conjugate and the native vitamin D<sub>3</sub> compete for the binding of the antibody. The quantity of bound antibodies is effected by means of agglutination of the microparticles. This can be determined for example directly by means of nephelometric analysis or turbidimetric 10 analysis.

Fig. 13 shows the scheme of a competitive binding assay, whereby the vitamin D binding protein is directly labelled, for example radioactively with <sup>125</sup>Iodine, or for 15 an electrochemoluminescence, with ruthenium(II)tris-(bipyridine)-NHS-ester. The marking may also be enzymes such as peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, etc., or may also be FITC.

20 Fig. 14 illustrates in a block diagram the different 1,25-dihydroxy vitamin D contents in serum from dialysis patients and from normal patients.

The known detection methods for proteins such as the 25 competitive ELISA are based on the principle that the compound to be detected competes with a binding protein or conjugate for a binding site. Then, the quantity of bound binding protein or conjugate is determined and on the basis of a calibration curve the concentration of the 30 compound to be detected is determined.

The test principles shown in the Figures can be carried over simply to other vitamin D derivatives. 1 $\alpha$ ,25-dihydroxy vitamin D<sub>2</sub> and D<sub>3</sub> are to be particularly 35 mentioned. In this case a binding protein or a receptor or



antibody must be selected which specifically recognises the 1 $\alpha$ ,25-dihydroxy vitamin D analog. The associated bifunctional 1 $\alpha$ ,25-dihydroxy derivative can be obtained enzymatically by means of reaction of 25-OH-vitamin D-3 $\beta$ -cyanoethylether with 25-OH-vitamin-D-1 $\alpha$ -hydroxylase, reduction to the amine and finally the addition of the second functional group. Further, derivatives of vitamin D<sub>2</sub> and vitamin D<sub>3</sub> are here proposed. The synthesis thereof can be effected through the route set out in Example 1.

#### EXAMPLES

##### **Example 1: Synthesis of 25-OH-Vit.-D<sub>3</sub>-3 $\beta$ -3' [6-N-(biotinyl)-hexamido]amidopropylether (4)**

All reactions were performed in the dark in a dry nitrogen atmosphere. Intermediate products were stored at -20°C. HPLC-pure solvents were employed. The 25-OH-vitamin D<sub>3</sub> was obtained from BIOMOL Feinchemikalien GmbH, Hamburg, the LC-BHNS (Long-Chain-Biotinyl-N- $\epsilon$ -amino caproyl-hydroxy-succinimide ester) from Sigma Chemie, and all further chemicals from Fluka, Darmstadt. The mass spectroscopy (FAB) was carried out with a Finigan-MAT-90, the NMR-measurements with a Bruker-ARX-400 (400 MHz) or a Bruker-ARC-250F (250 MHz).

##### *(i) 25-OH-Vitamin D<sub>3</sub>-3 $\beta$ -cyanoethylether (2)*

5 mg 25-OH-vitamin D<sub>3</sub> (12.5  $\mu$ Mol), dissolved in methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>), was transferred into a vial filled with nitrogen and the solvent was distilled off. The solid remainder was dissolved in 1 ml acetonitrile and mixed with 10 drops of a mixture of tertiary butanol and acetonitrile (9:1 v/v) and 130  $\mu$ Mol acrylonitrile (10 eq.) in 100  $\mu$ l acetonitrile [stock solution: 86  $\mu$ l

acrylonitrile (1.3 mMol) diluted with acetonitrile to 1 ml]. The clear solution was stirred for 15 minutes at 6°C. 6.25 μMol potassium hydride (0.5 eq.) in 25 μl tertiary butanol/acetonitrile (9:1 v/v) [stock solution: 10 mg KH (250 μMol) in 1 ml tertiary butanol/acetonitrile (9:1 v/v)] was added. The flocculation thereby arising dissolved again immediately. The mixture was stirred at 6°C. Repeated thin layer chromatography (DC) of individual samples with 20% petrolether in methyl-tert.-butylether (MTBE) on silica gel showed that after 10 minutes 90% of the initial compound had been reacted. After 15 minutes a few drops of the reaction mixture were prepared with about 5 drops of water and 0.5 ml MTBE. The thin film chromatography of the organic phase showed no further educt. After 40 minutes the entire reaction mixture was prepared with water/MTBE. 4 mg oleaginous product was obtained.

IR (NaCl/CH <sub>2</sub> Cl <sub>2</sub> ):	3422	OH
	2941, 2872	CH
	2252	nitrile
	1105	ether

The HPLC-analysis (3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) showed 93% product and 7% educt. Thus, 4 mg product contained 3.7 mg (8.2 μMol) target compound, which corresponds to a yield of 74%.

(ii) 25-OH-vitamin D<sub>3</sub>-3β-3' amino propylether (3)  
3.75 mg (8.3 μMol) nitrile from (i) was dissolved in 2 ml ether, to which was added 125 μMol lithium hydride dissolved in 1 ml ether (stock solution: 7 mg fresh finely powdered LiH in 7 ml ether) and stirred for 1 hour at room temperature in a nitrogen atmosphere. 169 μMol LiAlH<sub>4</sub> was added as suspension in 1 ml ether (base: 18 mg fresh

finely powdered  $\text{LiAlH}_4$  in 3 ml ether). After a further hour the mixture was prepared with 1 ml concentrated KOH, 5 ml  $\text{H}_2\text{O}$  and 4 x 20 ml MTBE. The thin film chromatography of a sample with 1:1 MTBE/petrolether on silica gel showed only the starting point. The diol was at  $R_f$  0.27; the nitrile at  $R_f$  0.4. The substance obtained was processed further without further analysis and purification.

(iii) 25-Hydroxy vitamin  $\text{D}_3$ - $3\beta$ -3' [6-N-(biotinyl)hexamido]-amidopropylether (4)

3 mg (6.6  $\mu\text{Mol}$ ) 25-OH-vitamin  $\text{D}_3$ - $3\beta$ -amino propylether (3) from (ii) was dissolved in 1 ml dimethylformamide (DMF). Then, in a nitrogen atmosphere, 3 mg (6.6  $\mu\text{Mol}$ ) LC-BNHS and 1  $\mu\text{l}$  (17.5  $\mu\text{Mol}$ ) triethylamine were added. Stirring for 18 hours at room temperature took place, the DMF was distilled off and the residue pre-purified with 20% methanol (MeOH) in  $\text{CH}_2\text{Cl}_2$ . 12 mg (>100%) of the substance so obtained was purified by means of HPLC (conditions: Knauer Kromasil-100, 5  $\mu\text{M}$ , 250 x 4 mm, 10% MeOH in  $\text{CH}_2\text{Cl}_2$ , 1.5 ml/min, OD 265 nm, 7 minutes). The yield amounted 1.2 mg (1.5  $\mu\text{Mol}$ ). This corresponds to 12% referred to the 25-OH-vitamin  $\text{D}_3$  and 18% referred to the nitrile compound.

Table I

Biotin-25-OH-Vitamin D <sub>3</sub>				
	H	Mult	Cc [Hz]	Assignment
6.42	1	Dd	5.7	NH (Biotin)
6.2	1	D	11	6
6.0	1	D	11	7
5.85	1	Dd	5.7	NH (Biotin)
5.55	2	M		3-O-CH <sub>2</sub> (28)
5.38	1	S		NH or OH
5.05	1	D	2	19
4.83	1	D	2	19
4.77	1	S		NH or OH
4.51	1	M		HC-NH I Biotin
4.33	1	M		HC-NH II Biotin
3.53	1	M		3
2.53	1	D	10	4
1.21	6	S		26,27-CH <sub>3</sub>
0.93	3	D	6	21-CH <sub>3</sub>
0.54	3	S		18-CH <sub>3</sub>

MS (Finigan MAT 90); (FAB): 797 (MH<sup>+</sup>) of 5.9.97 and 28.11.97; <sup>1</sup>H-NMR (Bruker ARX 400) in CDCl<sub>3</sub>/TMS at 400 MHz.

5 The data of the analysis are shown in table I.

**Example 2: Stability of 25-OH-Vit.-D<sub>3</sub>-3β-3' [6-N- (biotinyl) -hexamido]amidopropylether**

In each case 20 mg purified 25-OH-D<sub>3</sub>-biotin compound (25-OH-vitamin D<sub>3</sub>-3β-3' [6-N- (biotinyl) -hexamido]amidopropylether) from Example 1 was placed in an NMR test tube to which 1 ml solvent was added. The solvent was a mixture of deuterium chloroform:deuterium acetonitrile: D<sub>2</sub>O in the ratio 3:2:1 with a pH-value between 4 and 5. The samples were stored for 200 days under the conditions set out below and the NMR spectra were investigated at regular intervals.

- Sample 1: light excluded at -20°C;  
Sample 2 light excluded at +4-6°C;  
15 Sample 3: light excluded at room temperature;  
Sample 4: subject to strong light (on a window ledge) at room temperature.

Samples 1 and 2 showed no substantial alteration in NMR-spectrum over the entire time. An HPLC analysis confirmed that samples 1 and 2 were intact even after 200 days in protonic solvent. Sample 3 showed a minimal alteration of NMR spectrum after 100 days. The HPLC analysis indicated that more than 78% of the compound was still intact.  
25 Sample 4 was degraded after two months. The investigation of stability shows that the compound is very stable when light is excluded, even in protonic solvent and without cooling.

30 **Example 3: 25-Hydroxy vitamin D-ELISA with 25-Hydroxy vitamin D<sub>3</sub>-3β-3' [6-N- (biotinyl) -hexamido]amidopropylether**

The detection was effected in accordance with the principle illustrated in Fig. 2. For this purpose, 25-OH-vitamin D-3β-3' [6-N- (biotinyl)hexamido] amidopropylether

had to be bound to a solid phase via streptavidin.

*(i) Coating a microtitration plate with streptavidin*

Into each of the wells of a microtitration plate there was  
5 placed 100 ng streptavidin, dissolved in 200  $\mu$ l 60 mM  
NaHCO<sub>3</sub>, pH 9.6, and the plate incubated overnight at 4°C.  
The streptavidin solution in the well was removed and each  
well washed five times with 200  $\mu$ l washing buffer (PBS, pH  
7.4 with 0.05% Tween-20). Then, 250  $\mu$ l assay buffer was  
10 placed in each well. For the assay buffer, 5 g casein was  
dissolved in 100 ml 0.1 N NaOH and topped up with PBS, pH  
7.4 to 1 L volume. The solution was boiled for one hour,  
the volume supplemented to 1 litre with distilled water,  
the pH value set to 7.4 and 0.1 g thimerosal added to  
15 avoid growth of microbes. The wells in the microtitration  
plate were incubated for 1 hour at room temperature with  
assay buffer, then the assay buffer was removed and each  
well washed five times with in each case 200  $\mu$ l washing  
buffer.

20

*(ii) Binding of 25-Hydroxy vitamin D<sub>3</sub>-3 $\beta$ -3'[6-N-(biotinyl)-  
hexamido]amidopropylether*

Into each well there was introduced 100  $\mu$ l biotin-vitamin  
D-solution (10 ng 25-OH-vitamin D-3 $\beta$ -3'[6-N-(biotinyl)hex-  
25 amido]amidopropylether in 100  $\mu$ l washing buffer) and  
incubated for one hour at room temperature, in the dark  
whilst being shaken. Then, the biotin-vitamin D-solution  
was removed from the wells and each well washed five times  
in each case with 200  $\mu$ l washing buffer. In the liquid  
30 phase, there was effected a competitive binding of vitamin  
D binding protein in the presence of 25-OH-vitamin D from  
a standard or a sample.

*(iii) Sample preparation*

50 µl serum was mixed by vortexing with 200 µl ethanol<sub>abs</sub>  
(pre-cooled to -20°C) in a 1.5 ml Eppendorf reaction  
vessel and precipitated for 20 minutes at -20°C. The  
samples were centrifuged at maximum speed of rotation in  
an Eppendorf table centrifuge and the result removed and  
placed in the ELISA.

One can as a rule assume that plasma or serum samples are  
stable for about two weeks at 4°C. In the case of longer  
storage they must be deep frozen until they are analysed.  
Before storage, urine samples must be set to a pH-value  
between 6 and 8 with 1 N NaOH. Then, they may be stored at  
4°C for about 14 days; in the case of longer storage these  
also must be deep frozen until the analysis is carried  
out.

*(iv) Competitive binding*

In each case 100 µl vitamin D binding protein, isolated  
from goat serum (1:15000 in assay buffer with 3% (w/v) PEG  
6000) together with 10 µl standard, control or sample (10  
µl result from the sample preparation) was placed in the  
wells. The microtitration plate was incubated for 24 hours  
at 4°C in the dark and subject to shaking. Then, the  
solution was removed from the wells and the wells washed  
five times in each case with 200 µl washing buffer.

*(v) Detection of the competitive binding*

In each case 100 µl rabbit-anti-vitamin D-binding-protein  
(1:10000 diluted in assay buffer having 3% (w/v) PEG 6000)  
was introduced into the wells and incubated for 1 hour in  
the dark and subject to shaking, at room temperature. The  
solutions were removed from the wells and each well washed  
five times with in each case 200 µl washing buffer. The

quantitative determination was effected with 100 µl anti-rabbit-IgG-peroxidase (1:20000 diluted in washing buffer). Incubation took place for 1 hour at room temperature. Thereafter antibody solutions were taken off and each well  
5 washed five times in each case with 200 µl washing buffer. For the colour reaction 100 µl tetramethylbenzidine (TMB) substrate solution (ready for use, from NOVUM Diagnostika GmbH, Dietzenbach, Germany) was introduced into the wells. After 30 minutes the colour development was stopped by the  
10 addition of 50 µl 2 M H<sub>2</sub>SO<sub>4</sub> per well. The measurement of the optical density was effected at 450 nm. The following tables II and III show the pipetting scheme for the microtitration plate and the values for the optical density.

15 As standards there were employed solutions of 25-OH-vitamin D<sub>3</sub> in assay buffer with the following concentrations: 0, 8, 20, 50, 125 and 312 nMol/L (see calibration curve in Fig. 5A). As controls or samples  
20 there served four serums from patients having a D-hypovitaminosis (sample nos. 24, 203, 963, 965) and four randomly chosen normal serums (sample nos. NP 18, NP 25, NP 34, NP 37 - test series 3 and 4). For the vitamin D-deficiency serums additionally the 25-OH-vitamin D  
25 concentration was determined by means of competitive binding assay with the aid of <sup>3</sup>H-25-OH-vitamin D. As a further "controls" there served four solutions for which the respective concentrations of 25-OH-vitamin D were known from other determinations, either from manufacturer  
30 information or by means of a competitive binding assay (CBPA) with <sup>3</sup>H-25-OH-vitamin D.



Table II

Sample arrangement

Pipetting Scheme	Standard nMol/L	Duplicate value of column 1	Serum sample No.	Duplicate value of column 3	Controls	Duplicate value of column 5
Row/ Column	1	2	3	4	5	6
A	NSB	NSB	24	24	K1 (CPBA)	K1 (CPBA)
B	0	0	203	203	K2 (CPBA)	K2 (CPBA)
C	8	8	963	963	K3 (HPLC)	K3 (HPLC)
D	20	20	965	965	K4 (HPLC)	K4 (HPLC)
E	50	50	NP 18	NP 18		
F	125	125	NP 25	NP 25		
G	312	312	NP 34	NP 34		
H			NP 37	NP 37		

5

NSB: Non-specific binding buffer (Assay buffer without Vitamin D binding protein)

Table III

Measurement values after 30 minutes colour development

OD 450 nm	Standard	Duplicate value for column 1	Serum sample No.	Duplicate value for column 3	Controls	Duplicate value for column 5
Row/ Column	1	2	3	4	5	6
A	---	---	0,947	1,023	1,903	2,300
B	2,256	2,182	0,853	0,910	0,393	0,371
C	1,845	1,861	0,646	0,637	1,674	1,586
D	1,432	1,456	1,429	1,303	0,578	0,634
E	0,625	0,612	0,524	0,547		
F	0,287	0,261	0,454	0,419		
G	0,156	0,176	0,341	0,368		
H	---	---	0,421	0,386		
B <sub>max</sub>	2,801	2,676				

5

From the mean values of columns 1 and 2 and the known concentration of 25-OH-vitamin D, the calibration curve shown in Figure 5A was produced. The ordinate shows the optical density as mean value of the two measurements at 450 nm; the abscissa shows the concentration of 25-OH-vitamin D in nMol/l. The results are summarised in Table V.

15

**Example 4: Comparative binding analysis with  $^3\text{H}$ -25-OH-vitamin D as competitive partner**

Insofar as no other indication is given, all reagents, buffers and materials were the same as in above-mentioned Example 3. There served as competitive binding partner (tracer) tritium-labelled 25-OH-vitamin D<sub>3</sub>. Differing from Example 3, the measurement samples were purified by means of extraction (into individual values). For this purpose, in each case 50 µl sample [non-specific assay buffer NSB, standard, control, patients sample (plasma, serum or urine)] was introduced into a 1.5 ml disposable reaction container, 200 µl acetonitrile added, mixed, the container walls centrifuged free, and the mixture incubated for 20 to 30 minutes at 4°C. The mixture was centrifuged at 1700 x g for 10 minutes. The determinations were effected with the results using duplicate values.

For this purpose 25 µl clear result was transferred to a glass test tube (or into a special-RIA-container from Sarstedt, Darmstadt) and 10 µl tracer ( $^3\text{H}$ -25-OH-D), 300 µl assay buffer and 100 µl vitamin D-binding protein (not in NSB) added. The test tube contents were mixed, incubated for one hour at 4°C and, to remove non-bound radioactive tracer, 100 µl activated charcoal suspension (activated charcoal containing phosphate buffer with 0.1%  $\text{NaN}_3$ ) was added. The test tube content was mixed, incubated for 3 to 5 minutes at 4°C, and the active charcoal pelletized by means of centrifuging for 10 minutes at 1700 x g. Then, in each case 400 µl of the result was transferred to a counter container (7 ml) and, after the addition of 2 ml scintillator liquid such as Aquasafe™ 300 or HiSafe™ III, the radioactivity present in the result was counted (2 minutes in a beta-counter). The measurement value for the controls, after production of the calibration curve, are

shown in Table V.

The comparison with the ELISA according to Example 3 shows that for both assay procedures (ELISA and CBPA) it is the case that the normal range for 25-OH-vitamin D in plasma or serum is about 25 - 125 nmol/l. The sensitivity limit of the test systems was determined as  $B_0 + 2SD$ . It amounts to about 2.5 nmol/l.

Cross reactions: To serum treated with activated charcoal there was added 25-OH-vitamin  $D_2$  (125 nmol/l), 24,25-(OH) $_2$ -vitamin  $D_3$  (250 nmol/l) and 1,25-(OH) $_2$ -vitamin  $D_3$  (250 nmol/l). The 25-OH-vitamin  $D_2$  cross-reacted to 60%, the 24,25-(OH) $_2$ -vitamin  $D_3$  cross-reacted to 100%, whereas the 1,25-(OH) $_2$ -vitamin  $D_3$  show no cross-reactivity. Similar results have been found or expected also for multifunctional 25-OH-vitamin D conjugate in accordance with the invention.

Reproducibility: In repeat measurements (n=11) of a sample containing 25-dihydroxy vitamin  $D_3$  the following results were achieved. Similar applies also for measurements with the aid of the multifunctional 25-OH-vitamin D conjugate in accordance with the invention:

Table IV

Intra-assay variance:

	Number	Mean value nmol/l	Variance %
Sample 1	32	11.3	12.5
Sample 2	32	318	7.2

Inter-assay variance:

	Number	Mean value nmol/l	Variance %
Sample 1	9	9.9	17
Sample 2	9	310	11

5 Clinical:

	Number	Mean value nmol/l
Normal persons	35	54
Patients having hip joint fractures	43	9.5

10 For the samples mentioned in Example 3 the following 25-OH-vitamin D concentrations were determined with the methods according to Examples 3 and 4.

Table V

Serum sample No.	ELISA with 25-OH-D-Biotin nMol/L	CBPA with <sup>3</sup> H-25-OH-D nMol/L		Controls	ELISA with 25-OH-D-Biotin nMol/L	Alternative determination nMol/L
24	32,9	33,3		K1	Not measured	20 (a)
203	36,8	29,19		K2	76,8	75-125 (a)
963	48,9	38,4		K3	15,0	20-33 (b)
965	21,8	15,8		K4	51,3	72-120 (b)
NP 18	57,0					
NP 25	67,9		(a) CBPA with <sup>3</sup> H-25-OH-D (b) Manufacturer information			
NP 34	82,4					
NP 37	72,9					

5 The values indicated by the manufacturers were in general higher than the concentrations determined in the competitive binding assay. This suggests that in the supplied samples a significant part of the 25-OH-vitamin D had already decayed or transformed through the action of light.

**Example 5: Checking of the ELISA-determination by means of HPLC**

Thus, for various samples the 25-OH-vitamin D concentration was determined by means of the ELISA according to Example 3 and, for the purpose of checking, by means of HPLC. For the calibration curve, standards were employed having vitamin D<sub>3</sub> concentrations of 0, 8, 20,

50, 125 and 312 nMol/l. All samples and standards were measured with duplicate values. The 25-OH-vitamin D<sub>3</sub>-concentration of the samples was then determined on the basis of the calibration curve from the mean of the  
5 duplicate values.

The results are shown in the following table VI.

10

TABLE VI

Sample	25-OH-Vitamin D <sub>3</sub> (nMol/L)	
	HPLC	ELISA
1	20-33	30
2	72-120	76
3	79-102	96
4	<15	<Sensitivity limit
5	<15	7.4

15 **Example 6: Long term stability of 25-hydroxy vitamin D-conjugate in the ELISA detection.**

Calibration curves were repeated with the same standard solutions and reagents according to Example 3, after 60 and 100 days, in order to determine to what extent an ELISA detection using the biotin-25-OH-vitamin D-conjugate  
20 in accordance with the invention changed with the passage of time, when the reagents were stored in the interim at 4 to 6°C in the dark. The table below shows the respective optical densities after 30 minutes development (see Example 3).

TABLE VII

Standard	Standard	Duplicate value for column 1	After 60 Days	Duplicate value for column 3	After 100 Days	Duplicate value for Column 5
nMol/L	1	2	3	4	5	6
NSB	---	---	0.191	0.280	0.088	0.109
0	2.256	2.182	2.227	2.285	1.471	1.562
8	1.845	1.861	2.041	2.125	1.345	1.366
20	1.432	1.456	1.860	1.903	1.079	1.060
50	0.625	0.612	1.293	1.214	0.610	0.690
125	0.287	0.261	0.606	0.615	0.442	0.329
312	0.156	0.176	0.448	0.434	0.293	0.257

5 If the values of the various calibration curves, deducting the respective non-specific binding, are presented in a diagram (see Fig. 5B) it can readily be seen that the calibration curves have the same shape apart from a relative vertical displacement. This shows that the  
10 sensitivity and specificity of the ELISA test had not changed over the above-mentioned period of time.

**Example 7: 25(OH)-vitamin D<sub>3</sub>-ELISA-MTP with anti-vitamin-D-binding protein**

15

The trial was effected in substance in accordance with the protocol of Example 3 and with the principle illustrated in Fig. 4. The following buffers were employed: a) washing buffer: PBS, pH 7.4 with 0.05% Tween-20; b) assay buffer:  
20 5 g casein was dissolved in 100 ml 0.1 N NaOH and supplemented with PBS, pH 7.4 to 1 l. Then 3% (w/v) PEG-



6000 and 0.1 g Thimerosal<sup>TM</sup> were added. All incubations were effected in the dark and subject to shaking.

*(i) Coating the microtitration plate*

- 5 Into the wells of a microtitration plate there were introduced in each case 100  $\mu$ l rabbit-anti-vitamin D-binding protein in 60 mM NaHCO<sub>3</sub>, pH 9.6, and the plate incubated overnight at 4°C. The solutions were removed and each well washed five times with 200  $\mu$ l washing buffer.
- 10 Then, 250  $\mu$ l assay buffer was introduced into each well and the plate incubated for 1 hour at room temperature. The assay buffer was removed and each well was washed five times with in each case 200  $\mu$ l washing buffer.

15 *(ii) Sample preparation*

- 50  $\mu$ l serum, plasma or standard was mixed in a 1.5 ml Eppendorf reaction container with 200  $\mu$ l ethanol<sup>abs</sup> (pre-cooled to -20°C), vortexed and then precipitated for 20 minutes at -20°C. The samples were centrifuged in an
- 20 Eppendorf table centrifuge at maximum rotations. The result was taken and employed in the ELISA.

*(iii) ELISA*

- Firstly, into each individual well 100  $\mu$ l vitamin D-binding protein, diluted in assay buffer, was introduced
- 25 and incubated for 1 hour at room temperature. The plate was then knocked out and each individual well washed five times in each case with 200  $\mu$ l washing buffer.
- 30 Thereafter, there was introduced into the wells in each case 100  $\mu$ l biotin-vitamin D, diluted in assay buffer, together with 10  $\mu$ l standard, sample or control. The plate was incubated for 24 hours at 4°C. The solutions were

again removed and each well washed five times in each case with 200 µl washing buffer.

As a third step there was introduced into the wells in each case 100 µl peroxidase-coupled streptavidin in a 1:10000-dilution in washing buffer, and incubated for 45 minutes at room temperature. The plate was knocked out and each well washed five times in each case with 200 µl washing buffer.

For the colour reaction, there was introduced into each well 100 µl TMB-substrate solution. After sufficient colour development (30 minutes) the reaction was stopped with 50 µl 2M H<sub>2</sub>SO<sub>4</sub> per well. The measurement of the optical density was detected at 450 nm. Similar to same results were obtained as in Example 3 or table V.

**Example 8: Content of a test pack or a reagent set for the detection of 25-hydroxy vitamin D and 1α,25-dihydroxy vitamin D:**

Content of the test pack or test reagents and their preparation:

Standards, for example 6 vials of 25-OH-vitamin D standards with the concentrations 0, 8, 20, 50, 125 and 312 nmol/l; ready for use in washing buffer.

Microtitration plates, for example coated with streptavidin, sterile packed and pre-washed.

Buffer solutions, for example washing buffer, NSB-buffer and assay buffer, stopper solution.

Controls, for example 2 vials 25-OH-vitamin D controls in human serum. Control 1 (30 nmol 25-OH-D/L), control 2 (80 nMol 25-OH-D/L).

- 5 Tracer, for example a vial with biotin-vitamin D (25-OH-vitamin D<sub>3</sub>-3β-3' [6-N-(biotinyl)-hexamido]amidopropylether) in washing buffer (100 ng/ml).

- 10 Vitamin D-binding protein, for example a vial with binding protein from goat serum in phosphate buffer with 0.1% NaN<sub>3</sub> as stabilising agent.

- Marker, for example a vial of anti-rabbit-IgG-peroxidase in washing buffer.

- 15 TMB-developer-solution, for example a vial of stabilised tetramethylbenzidine-developer solution in washing buffer.

20 **Example 9: ELISA for the quantitative detection of 1,25-dihydroxy vitamin D**

The detection of 1,25-vitamin D<sub>3</sub> was effected in accordance with the principle illustrated in Fig. 2, except that 1,25-dihydroxy vitamin D<sub>3</sub>-biotin compound served as tracer.

- 25 In the competition, 1,25-dihydroxy vitamin D<sub>3</sub> from a standard or a sample, together with a 1,25-dihydroxy vitamin D binding protein, a monoclonal mouse-anti-1α,25-dihydroxy vitamin D-antibody (B. Mawer et al. in Steroids, 1985, 46, 741-754), were brought together. The 1,25-dihydroxy vitamin D<sub>3</sub> from a standard or a sample and the immobilised 1,25-dihydroxy vitamin D<sub>3</sub>-biotin compound then compete for the binding site of the antibody. The detection is effected by means of peroxidase-labelled antibodies (goat-anti-mouse-IgG-POX).

35

10020"360260

(i) The coating of the microtitration plate with streptavidin was effected as in Example 3, whereby however the washing buffer contained 0.1% Triton<sup>TM</sup> X-100 as a detergent. Otherwise than as in example 3, the wells in the microtitration plate were no longer washed with washing buffer after the treatment with streptavidin solution, but in each case treated for 1 hour with 250 µl aqueous sorbitol solution (Karion<sup>TM</sup> F 1:4 in water). The binding of the tracer (1,25-dihydroxy vitamin D-biotin) was effected as in Example 3, except that there was introduced into each well 200 µl tracer solution (20 ng 1,25-dihydroxy vitamin D<sub>3</sub>-3β-3' [6-N-(biotinyl)-hexamido]-amidopropylether in washing buffer). The 1,25-dihydroxy vitamin D-biotin was synthesised as schematically illustrated in Fig. 1, except that after the first step the excess 3-cyanoethylated 1-OH-vitamin D intermediate compound was isolated. There can however, also be isolated as desired one of the following intermediate compounds or, after a mixed synthesis, specifically the 1,25-dihydroxy vitamin D<sub>3</sub>-3β-3' [6-N-(biotinyl)-hexamido]amidopropylether by means of HPLC.

(ii) Since in human serum the ratio of 25-OH-vitamin D<sub>3</sub> to 1,25-dihydroxy vitamin D<sub>3</sub> as rule is in the range of 1000:1 the quantitative detection of 1,25-dihydroxy vitamin D requires a thorough preparation of the samples by means of a combined distribution and absorption chromatography. In the first step, for this purpose, Extrelut<sup>TM</sup> Kieselguhr columns (Merck, Darmstadt) are brought to equilibrium each with 500 µl tris-buffer and then there is applied to the columns in each case 500 µl of a standard, control or investigation sample - in duplicates; the samples can then draw into the columns for 10 minutes. The separation of the vitamin D-compounds from the Extrelut<sup>TM</sup> columns was effected by means of four times 1 ml diisopropylether at

intervals in each case of 3 minutes. The Extrelut<sup>TM</sup> extract was directly transferred to a silica cartridge (Merck, Darmstadt) and the Extrelut<sup>TM</sup> columns disposed of. The silica columns were washed five times with 2 ml isopropanol/hexane (4/96 v/v) and 3 times with 2 ml isopropanol/hexane (6/94 (v/v)). The 1,25-dihydroxy vitamin D was then eluted from the silica columns with two times 2 ml isopropanol/hexane (25/75 v/v) and dried in a nitrogen atmosphere at 37°C or in a vacuum centrifuge. The standard and investigation samples were finally taken up in 20 µl ethanol p.a., in each case with 200 µl mouse-anti-1,25-dihydroxy vitamin D-antibody solution (1:150000 in RRA assay buffer: 50 mM KH<sub>2</sub>PO<sub>4</sub>, 15 mM KCl, 1.25 mM EDTA, 3mM mercaptoethanol, pH 7.5) and pre-incubated for 1 hour at room temperature - as far as possible at the same time as the application of the 1,25-dihydroxy vitamin D-biotin tracer to the streptavidin treated microtitration plate.

(iii) The wells of the tracer-coated microtitration plate were washed five times in each case with 300 µl Triton<sup>TM</sup> washing buffer and knocked out onto absorptive paper. Then, 200 µl antibody sample solution from the pre-incubation was transferred into the wells and incubated for 1 hour in the dark and subject to shaking at room temperature. After the removal of the solutions from the wells they were washed five times in each case with 200 µl washing buffer. The quantitative determination was effected analogously to Example 3 by means of 1 hour incubation with 200 µl rabbit-anti-mouse-IgG-peroxidase (1:10000 in washing buffer), at room temperature, five times washing of the wells with 300 µl washing buffer, a colour reaction in the dark with 200 µl TMB substrate solution (ready for use from NOVUM Diagnostika GmbH, Dietzenbach) stopping of the colour reaction after 15

minutes by means of the addition of 50  $\mu$ l 2 M  $H_2SO_4$  and determination of the extinction at 450 nm.

The following table VIII shows the results of the 1,25-  
5 dihydroxy vitamin D determination in serum from 11  
dialysis patients and six randomly chosen normal persons.  
For determination of the calibration curve or as standard,  
there were employed solutions of 1,25-dihydroxy vitamin D  
in assay buffer with the following concentration: 0, 6.6,  
10 20, 60 and 180 pg/ml (see calibration curve in Fig. 5C).

TABLE VIII

Pipetting scheme	Standard 1,25-OH-Vit.D (pg/ml)	Remarks	OD 450 nm	Douple value	Mean value	Standard deviation
1	0	Calibration curve - See Fig. 5c	0.784	0.781	0.782	0.002
2	6.6		0.732	0.741	0.737	0.006
3	20		0.682		0.628	
4	60		0.484		0.484	
5	180		0.233		0.233	
Control Serum 98-08-295	50.1	Desired range: 23 – 63 pg/ml Mean: 43.21 pg/ml S.D.: 6.62 pg/ml	0.493			
Sample Number	Measured value (pg/ml)					
1	6.5	Serum samples from dialysis patients  Mean value: 20.5 S.D. 17.2 Median 13.4	0.705	0.733	0.719	0.020
2	39.1		0.564	0.508	0.536	0.040
3	57.8		0.475	0.458	0.466	0.012
4	12.2		0.672	0.687	0.679	0.010
5	0.3		0.776	0.774	0.775	0.002
6	4.0		0.667	0.816	0.741	0.105
7	13.4		0.642	0.700	0.671	0.041
8	39.4		0.565	0.504	0.535	0.043
9	22.1		0.619	0.618	0.000	
10	22.6		0.531	0.700	0.616	0.119
11	8.6		0.705		0.705	
Comp. samples						
1	52.9	Serum sample from normal persons  Mean value 46.0 S.D 9.7 Median 47.8	0.502	0.464	0.483	0.027
2	42.6		0.518	0.525	0.522	0.005
3	35.3		0.522	0.583	0.553	0.043
4	32.9		0.571	0.556	0.563	0.010
5	59.2		0.410	0.514	0.462	0.073
6	53.1		0.485	0.480	0.482	0.003

Fig. 14 illustrates in a bar chart once again the values found for dialysis and normal patients, in accordance with which values the serum of dialysis patients on average contains significantly less active 1,25-dihydroxy vitamin D. The great variance of the values for the dialysis patients shows also the need to more closely monitor the content of active 1,25-dihydroxy vitamin D in the serum of dialysis patients, in order better to counter the typical consequences of a vitamin D deficiency.




C L A I M S  
(as originally filed)

1. Vitamin D derivative having the formula:

5

10

15



(I)

20

wherein:

- O represents the oxygen atom of an ether group;
- X represents a substituted or non-substituted hydrocarbon group of 0.8 to 4.2 nm length, which may have the usual heteroatoms such as S, O, N or P;
- Y represents hydrogen or hydroxy;
- A represents a tracer group, which can be bound with high affinity by a binding protein;
- R represents a substituted or non-substituted hydrocarbon side group of vitamin D or of a vitamin D metabolite, a side group of vitamin D<sub>2</sub> or D<sub>3</sub>, the 25-OH-side group of vitamin D<sub>2</sub> or D<sub>3</sub>.

30

2. Vitamin D derivative according to claim 1, wherein A is selected from biotin, digoxigenin, tyrosine, FITC substituted tyrosine, substituted amino acid, charac-

35

teristic amino acid and peptide sequences, FITC, proteins and peptide groups, protein A, protein G, vitamin D derivatives, 25-OH-vitamin D.

- 5 3. Vitamin D derivative according to claim 1, wherein A is compound of the formula (I) which in the  $3\beta$ -position is connected via an ether bridge to the spacer group X.
- 10 4. Vitamin D derivative according to any of claims 1 to 3, wherein the spacing group has the length of 0.8 to 2 nm, particularly preferably 0.9 to 1.5 nm.
- 15 5. Vitamin D derivative according to any of claims 1 to 4, wherein the spacing group is an amino carboxylic acid radical, an amino undecanoic acid radical or an amino polyether radical.
- 20 6. Method for producing vitamin D-derivative according to any of claims 1 to 5, including the steps: a) cyanoethylation of 25-hydroxy vitamin D with acrylonitrile in a mixture with acetonitrile, potassium hydride and tertiary butanol and b) reduction of the nitrile group with  $\text{LiH/LiAlH}_4$ .
- 25 7. Method for the quantitative detection of 25-hydroxy- and  $1\alpha,25$ -dihydroxy vitamin D metabolite in a sample, characterised in that a vitamin D derivative according to any of claims 1 to 5 is employed as a binding partner.
- 30 8. Method according to claim 7, wherein the method includes a protein binding analysis.
- 35 9. Method according to claim 8, wherein the method

includes the binding to a receptor.


10. Method according to claim 8, wherein the method includes a binding to an antibody.
- 5
11. Method according to claim 10, wherein the method is a competitive immunoassay, selected from RIA, EIA/ELISA, LiA and FiA.
- 10 12. Method according to claim 10, wherein the method is a sandwich immunoassay, selected from IRMA, IEMA/EUA, ILMA (immunoluminescence assay) and IFMA (immunofluorescence assay).
- 15 13. Method according to any of claims 7 to 12, including a solid phase, selected from a microtitration plate and other solid carriers, microparticles, preferably of agarose, polymeric material, cellulose, magnetic microparticles.
- 20 14. Method according to any claims 7 to 13, wherein the method is effected in a manner which can be automated, in liquid or solid phase.
- 25 15. Method for the detection of 25-hydroxy- and 1 $\alpha$ ,25-dihydroxy vitamin D-metabolites according to any of claims 7 to 14, including the steps: a) coating of a solid carrier with streptavidin; b) addition of biotin-vitamin D derivative according to any of
- 30 claims 1 to 5; c) addition of the sample and a defined quantity of vitamin D-binding-protein; d) detection of the bound binding protein with labelled antibodies against vitamin D-binding protein.
- 35 16. Method for the detection of 25-hydroxy- and 1 $\alpha$ ,25-

5 dihydroxy vitamin D metabolites according to any of claims 7 to 14, including the steps: a) coating a carrier with antibodies against vitamin D-binding protein; b) addition of vitamin D binding protein; c) addition of the sample and a defined quantity of biotin coupled vitamin D-derivative according to claim 1; d) detection of the quantity of bound derivative with labelled streptavidin.

10 17. Method according to any of claims 7 to 16, whereby the detection is effected by means of marking with an enzyme which catalyses a detection reaction.

15 18. Reagent set for the detection of 25-hydroxy- and 1 $\alpha$ ,25-dihydroxy vitamin D metabolites in accordance with a method according to any of claims 7 to 17, characterised in that it has a standardised quantity of solid material or solution of a vitamin D-derivative according to any of claims 1 to 5.

20



Peroxidase

2/15

anti-vitamin D-binding protein, peroxidase-labelled




Fig. 2

3/15




Fig. 3

4/15





Fig. 4




5/15

Fig. 5A




6/15

Fig. 5B



7/15



1,25 Dihydroxyvitamin D [pg/ml] Fig. 50

8/15




Fig. 6




Fig. 7

9/15




Fig. 8

anti-vitamin D-binding  
protein, peroxidase-labelled

10/15




Fig. 9

11/15




Fig. 10




Fig. 11



13/15




Fig. 12

14/15




Fig. 13

15/15




Fig. 14

## BIRCH, STEWART, KOLASCH &amp; BIRCH, LLP

P.O. Box 747 • Falls Church, Virginia 22040-0747  
 Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
 YOU MUST  
 COMPLETE THE  
 FOLLOWING

# COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title:

FUNCTIONAL VITAMIN D DERIVATIVES AND METHOD OF DETERMINING 25-HYDROXY- AND 1 $\alpha$ -25-DIHYDROXY VITAMIN D

Fill in Appropriate  
 Information -  
 For Use Without  
 Specification  
 Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on December 22, 2000 as  
 United States Application Number 09/720,338  
 and amended on December 22, 1999 (if applicable) and/or  
 the specification was filed on June 25, 1998 as PCT  
 International Application Number PCT/EP99/04418; and was  
 amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

## Prior Foreign Application(s)

## Priority Claimed

Insert Priority  
 Information:  
 (if appropriate)

<u>198 28 379.2</u> (Number)	<u>DE</u> (Country)	<u>June 25, 1998</u> (Month/Day/Year Filed)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<u>198 40 435.2</u> (Number)	<u>DE</u> (Country)	<u>September 4, 1988</u> (Month/Day/Year Filed)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Month/Day/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below.

Insert Provisional  
 Application(s):  
 (if any)

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Country	Application Number	Date of Filing (Month/Day/Year)
_____	_____	_____
_____	_____	_____

Insert Requested  
 Information:  
 (if appropriate)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112.1 acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S.  
 Application(s):  
 (if any)

_____ (Application Number)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
_____ (Application Number)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)

RECEIVED  
 FEB 27 2001  
 Group 2:00

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joc McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailcy	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)
Gary L. Yacura	(Reg. No. 35,416)	Thomas S. Auchterlonie	(Reg. No. 37,275)
Mark J. Nuell	(Reg. No. 36,623)		

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP** or Customer No. 2292  
P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE  
THE  
FOLLOWING:

Full Name of First  
Inventor (Name of  
Inventor)  
Insert Last, First,  
Document in Serial

Insert Residence  
Insert Citizenship

Insert Full Office  
Address

Full Name of Second  
Inventor, if any:  
not above

Full Name of Third  
Inventor, if any:  
not above

Full Name of Fourth  
Inventor, if any:  
not above

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Franz Paul ARMBRUSTER		<i>Franz Paul Armbuster</i>	1.2.2001
Residence (City, State & Country)		CITIZENSHIP	
Bobenheim-Roxheim, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Mittelstrasse 24, 67240 Bobenheim-Roxheim, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Wolfgang VOELTER			
Residence (City, State & Country)		CITIZENSHIP	
Tübingen, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Panoramastrasse 71, 72070 Tübingen, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Jens TAMPE (formerly SCHWING)			
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Bingener Strasse 20, 80993 München, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Christian BIRKMAYER			
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Reitmorstrasse 54, 80538 München, GERMANY			

\*DATE OF SIGNATURE

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT AND DESIGN APPLICATIONS**

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title:

FUNCTIONAL VITAMIN D DERIVATIVES AND METHOD OF DETERMINING 25-HYDROXY- AND 1 $\alpha$ -25-DIHYDROXY VITAMIN DFill in Appropriate  
Information -  
For Use Without  
Specification  
Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on December 22, 2000 asUnited States Application Number 09/720,338and amended on December 22, 1999 (if applicable) and/orthe specification was filed on June 25, 1998 as PCTInternational Application Number PCT/EP99/04418 and was

amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows:

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Insert Priority  
Information:  
(if appropriate)**Prior Foreign Application(s)****Priority Claimed**

<u>198 28 379.2</u>	<u>DE</u>	<u>June 25, 1998</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Month/Day/Year Filed)	Yes	No
<u>198 40 435.2</u>	<u>DE</u>	<u>September 4, 1988</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Month/Day/Year Filed)	Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Month/Day/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below.

Insert Provisional  
Application(s):  
(if any)

_____	_____
(Application Number)	(Filing Date)
_____	_____
(Application Number)	(Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Insert Requested  
Information:  
(if appropriate)

Country	Application Number	Date of Filing (Month/Day/Year)
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S.  
Application(s):  
(if any)

_____	_____	_____
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
_____	_____	_____
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrill C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Muller	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joc McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailey	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)
Gary D. Yacura	(Reg. No. 35,416)	Thomas S. Auchterlonie	(Reg. No. 37,275)
Mark J. Nuell	(Reg. No. 36,623)		

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP** or **Customer No. 2292**  
P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE  
THE  
FOLLOWING:

Full Name of First  
Inventor (Name of  
Inventor)  
Insert Date Filed  
Document is Signed

Insert Residence  
Inventor's Citizenship

Insert Post Office  
Address

Full Name of Second  
Inventor, if any:  
see above

Full Name of Third  
Inventor, if any:  
see above

Full Name of Fourth  
Inventor, if any:  
see above

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Franz Paul ARMBRUSTER			
Residence (City, State & Country)		CITIZENSHIP	
Bobenheim-Roxheim, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Mittelstrasse 24, 67240 Bobenheim-Roxheim, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Wolfgang VOELTER		<i>Wolfgang Voelter</i>	2.2.2001
Residence (City, State & Country)		CITIZENSHIP	
Tübingen, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Panoramastrasse 71, 72070 Tübingen, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Jens TAMPE (formerly SCHWING)			
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Bingener Strasse 20, 80993 München, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Christian BIRKMAYER			
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Reitmorstrasse 54, 80538 München, GERMANY			

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT AND DESIGN APPLICATIONS**

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title:

FUNCTIONAL VITAMIN D DERIVATIVES AND METHOD OF DETERMINING 25-HYDROXY- AND 1 $\alpha$ -25-DIHYDROXY VITAMIN DFill in Appropriate  
Information -  
For Use Without  
Specification  
Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on December 22, 2000 asUnited States Application Number 09/720,338and amended on December 22, 1999 (if applicable) and/orthe specification was filed on June 25, 1999 as PCTInternational Application Number PCT/EP99/04418; and was

amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows:

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Insert Priority  
Information:  
(if appropriate)**Prior Foreign Application(s)****Priority Claimed**

<u>198 28 379.2</u> (Number)	<u>DE</u> (Country)	<u>June 25, 1998</u> (Month/Day/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>198 40 435.2</u> (Number)	<u>DE</u> (Country)	<u>September 4, 1988</u> (Month/Day/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Month/Day/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Insert Provisional  
Application(s):  
(if any)

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Country	Application Number	Date of Filing (Month/Day/Year)
_____	_____	_____
_____	_____	_____

Insert Requested  
Information:  
(if appropriate)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S.  
Application(s):  
(if any)

_____ (Application Number)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
_____ (Application Number)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)



I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrill C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Muller	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joc McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailey	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)
Gary D. Yacura	(Reg. No. 35,416)	Thomas S. Auchterlonie	(Reg. No. 37,275)
Mark J. Nuell	(Reg. No. 36,623)		

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**

or

Customer No. 2292

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE  
THE  
FOLLOWING:

Full Name of Inventor  
or Joint Inventor  
Insert Name of  
Inventor  
Insert Date This  
Statement is Signed

Insert Residence  
Insert City, State & Country

Insert Post Office  
Address

Full Name of Second  
Inventor, if any:  
Insert Name

Full Name of Third  
Inventor, if any:  
Insert Name

Full Name of Fourth  
Inventor, if any:  
Insert Name

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Franz Paul ARMBRUSTER			
Residence (City, State & Country)		CITIZENSHIP	
Bobenheim-Roxheim, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Mittelstrasse 24, 67240 Bobenheim-Roxheim, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Wolfgang VOELTER			
Residence (City, State & Country)		CITIZENSHIP	
Tübingen, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Panoramastrasse 71, 72070 Tübingen, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Jens TAMPE (formerly SCHWING)		Jens Tampe	02.02.2004
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Bingener Strasse 20, 80993 München, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Christian BIRKMAYER			
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Reitmorstrasse 54, 80538 München, GERMANY			

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**P.O. Box 747 • Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 • Facsimile: (703) 205-8050PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT AND DESIGN APPLICATIONS**

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title:

FUNCTIONAL VITAMIN D DERIVATIVES AND METHOD OF DETERMINING 25-HYDROXY- AND 1 $\alpha$ -25-DIHYDROXY VITAMIN DFill in Appropriate  
Information -  
For Use Without  
Specification  
Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on December 22, 2000 asUnited States Application Number 09/720,338;and amended on December 22, 1999 (if applicable) and/orthe specification was filed on June 25, 1998 as PCTInternational Application Number PCT/EP99/04418; and was

amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Insert Priority  
Information:  
(if appropriate)**Prior Foreign Application(s)****Priority Claimed**198 28 379.2  
(Number)DE

(Country)

June 25, 1998

(Month/Day/Year Filed)

☒ Yes ☐ No198 40 435.2  
(Number)DE

(Country)

September 4, 1988

(Month/Day/Year Filed)

☒ Yes ☐ No

(Number)

(Country)

(Month/Day/Year Filed)

☐ Yes ☐ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below.

Insert Provisional  
Application(s):  
(if any)

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Country

Application Number

Date of Filing (Month/Day/Year)

Insert Requested  
Information:  
(if appropriate)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Insert Prior U.S.  
Application(s):  
(if any)

(Application Number)

(Filing Date)

(Status - patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status - patented, pending, abandoned)

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Raymond C. Stewart	(Reg. No. 21,066)	Terrill C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailcy	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)
Gary D. Yacura	(Reg. No. 35,416)	Thomas S. Auchterlonie	(Reg. No. 37,275)
Mark J. Nuell	(Reg. No. 36,623)		

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**

or Customer No. 2292

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE  
THE  
FOLLOWING:

Full Name of First  
or Sole Inventor  
(Name of  
Inventor)  
Insert Last Name  
First Name Initial

Insert Residence  
Insert Citizenship

Insert Post Office  
Address

Full Name of Second  
Inventor, if any:  
see above

Full Name of Third  
Inventor, if any:  
see above

Full Name of Fourth  
Inventor, if any:  
see above

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Franz Paul ARMBRUSTER			
Residence (City, State & Country)		CITIZENSHIP	
Bobenheim-Roxheim, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Mittelstrasse 24, 67240 Bobenheim-Roxheim, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Wolfgang VOELTER			
Residence (City, State & Country)		CITIZENSHIP	
Tübingen, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Panoramastrasse 71, 72070 Tübingen, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Jens TAMPE (formerly SCHWING)			
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Bingener Strasse 20, 80993 München, GERMANY			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Christian BIRKMAYER		<i>Christian Birkmayer</i>	Feb 03/2001
Residence (City, State & Country)		CITIZENSHIP	
München, GERMANY		German	
MAILING ADDRESS (Complete Street Address including City, State & Country)			
Reitmorsstrasse 54, 80538 München, GERMANY			

\*DATE OF SIGNATURE